4/24
04:00 pm
mdgl
Madrigal Statement on the Passing of Dr. Stephen Harrison
Medium
Report
Madrigal Statement on the Passing of Dr. Stephen Harrison
4/24
01:16 pm
mdgl
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage [Seeking Alpha]
Low
Report
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage [Seeking Alpha]
4/23
08:12 am
mdgl
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 [Yahoo! Finance]
4/23
08:00 am
mdgl
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
Low
Report
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
4/22
08:09 am
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is now covered by analysts at Bank of America Co.. They set an "underperform" rating and a $150.00 price target on the stock.
Medium
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is now covered by analysts at Bank of America Co.. They set an "underperform" rating and a $150.00 price target on the stock.
4/16
04:05 pm
mdgl
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4/12
02:04 am
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.
4/10
10:26 am
mdgl
2 Under-the-Radar Growth Stocks to Consider [Yahoo! Finance]
Low
Report
2 Under-the-Radar Growth Stocks to Consider [Yahoo! Finance]
4/9
08:13 am
mdgl
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis [Yahoo! Finance]
4/9
08:00 am
mdgl
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Medium
Report
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
4/5
09:19 am
mdgl
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) [Yahoo! Finance]
Low
Report
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) [Yahoo! Finance]
4/3
04:05 pm
mdgl
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4/3
08:51 am
mdgl
1 No-Brainer Growth Stock to Buy Now [Yahoo! Finance]
Low
Report
1 No-Brainer Growth Stock to Buy Now [Yahoo! Finance]
3/29
04:54 am
mdgl
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? [Yahoo! Finance]
Medium
Report
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? [Yahoo! Finance]
3/28
11:04 pm
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.
3/26
12:17 pm
mdgl
Liver-Assessment Tool Hepatoscope® Cleared for Use in U.S. and Europe Just as First Medication for MASH* Gains FDA Approval [Yahoo! Finance]
Low
Report
Liver-Assessment Tool Hepatoscope® Cleared for Use in U.S. and Europe Just as First Medication for MASH* Gains FDA Approval [Yahoo! Finance]
3/26
11:21 am
mdgl
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock [Yahoo! Finance]
Low
Report
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock [Yahoo! Finance]
3/22
06:23 am
mdgl
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? [Yahoo! Finance]
Medium
Report
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? [Yahoo! Finance]
3/20
11:37 am
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target raised by analysts at Evercore ISI from $325.00 to $405.00. They now have an "outperform" rating on the stock.
Low
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target raised by analysts at Evercore ISI from $325.00 to $405.00. They now have an "outperform" rating on the stock.
3/19
11:11 pm
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.
3/19
10:08 am
mdgl
Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming [CNBC]
Low
Report
Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming [CNBC]
3/19
05:55 am
mdgl
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? [Yahoo! Finance]
Medium
Report
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? [Yahoo! Finance]
3/18
11:58 pm
mdgl
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
Medium
Report
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
3/18
04:20 pm
mdgl
Madrigal Pharmaceuticals Announces Proposed Public Offering [Yahoo! Finance]
Medium
Report
Madrigal Pharmaceuticals Announces Proposed Public Offering [Yahoo! Finance]
3/18
04:04 pm
mdgl
Madrigal Pharmaceuticals Announces Proposed Public Offering
Medium
Report
Madrigal Pharmaceuticals Announces Proposed Public Offering